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Mitochondrial myopathy and sideroblastic anemia (MLASA) is a rare, autosomal recessive oxidative phosphory-
lation disorder specific to skeletal muscle and bone marrow. Linkage analysis and homozygosity testing of two
families with MLASA localized the candidate region to 1.2 Mb on 12q24.33. Sequence analysis of each of the six
known genes in this region, as well as four putative genes with expression in bone marrow or muscle, identified
a homozygous missense mutation in the pseudouridine synthase 1 gene (PUS1) in all patients with MLASA from
these families. The mutation is the only amino acid coding change in these 10 genes that is not a known poly-
morphism, and it is not found in 934 controls. The amino acid change affects a highly conserved amino acid, and
appears to be in the catalytic center of the protein, PUS1p. PUS1 is widely expressed, and quantitative expression
analysis of RNAs from liver, brain, heart, bone marrow, and skeletal muscle showed elevated levels of expression
in skeletal muscle and brain. We propose deficient pseudouridylation of mitochondrial tRNAs as an etiology of
MLASA. Identification of the pathophysiologic pathways of the mutation in these families may shed light on the
tissue specificity of oxidative phosphorylation disorders.
Mitochondrial myopathy and sideroblastic anemia
(MLASA [MIM 600462]) is a rare autosomal recessive
disorder of oxidative phosphorylation and iron metab-
olism. Elsewhere, we have described a Jewish Iranian
family living in the United States with four individuals
affected with MLASA (Casas and Fischel-Ghodsian
2004). Linkage analysis and homozygosity testing in this
family and in an elsewhere described family from Israel,
which originated from the same Iranian town as the U.S.
family (Inbal et al. 1995), localized a candidate region
within 1.2 Mb of chromosome 12q24.33 (Casas et al.,
in press).
Analysis of the electronically available expression in-
formation in OMIM, UniGene, EST (at NCBI), Ensembl,
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and TIGR databases showed evidence for expression in
at least one of the affected tissues (bone marrow and
muscle) in 10 genes in the 1.2-Mb candidate region.
Complete coding regions of the candidate genes, includ-
ing 5′ UTRs and splice sites (intron-exon junctions), were
sequenced directly in patients and obligate carriers (par-
ents) from family 1 (fig. 1). We identified a total of 10
nucleotide substitutions in the coding regions of six
genes (table 1). Six nucleotide substitions led to amino
acid substitutions. Analysis of the electronic databases
showed that five are common polymorphisms. Only one
sequence change, a CrT mutation at mRNA position
656 in exon 3 of the PUS1 gene (fig. 1A), results in a
nonconservative amino acid change (R116W) and con-
stitutes a novel change not present in SNP and/or EST
databases. Direct sequencing of exon 3 of PUS1, as well
as RFLP analysis using restriction endonuclease NciI, in
16 members of the two families revealed all affected
individuals to be homozygous, all parents to be hetero-
zygous, and all unaffected siblings to be either hetero-
zygous carriers or negative for the C656T mutation (fig.
1B). C656T results in a nonconservative amino acid
change from arginine to tryptophan at position 116 of
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Figure 1 Homozygous mutation in PUS1 causes MLASA. A, Map of PUS1 with exons in dark blue. The start codon and mutated position
656 in exon3 are identified. B, Two pedigrees of MLASA families shown with their sequencing and RFLP results for the mutation at position
656 in the PUS1 gene. Affected individuals are indicated by dark blue symbols. The mutation abolishes the restriction site for NciI.
the protein. Arginine and tryptophan differ greatly in
their physical qualities, and the two databases focused
on amino acid properties, EMBL (Betts and Russel 2003)
and the Centre for Molecular and Biomolecular Infor-
matics, do not consider this substitution to be a benign
polymorphic change. The mutation was not present in
204 DNA samples from Arab Israeli and Spanish/Italian
families with mitochondrial deafness or in 730 Jewish
and non-Jewish individuals from families with inflam-
matory bowel disease; all 934 controls contained a nor-
mal nucleotide in the homozygous state.
Arginine 116 (116R) is located in the highly conserved
domain RTDKGV and is preserved perfectly in the eu-
karyotic and prokaryotic pus1 proteins (fig. 2). The
RTDKGV sequence motif appears to be the catalytic
center of the protein. It is conserved in all pseudouridine
synthases of the TruA, RluA, RsuA, and TruB protein
families (Koonin 1996) and contains the invariant as-
partate residue (D) necessary for catalysis in the mem-
bers of TruA, TruB, and RluA pseudouridine synthases
(Huang et al. 1998; Gu et al. 1999; Ramamurthy et al.
1999; Ansmant et al. 2000). In the E. coli pseudouridine
synthase 1, arginine residue homologous to the human
116R has been shown to interact through hydrogen
bonds with the aspartate in the catalytic center (Foster
et al. 2000).
We evaluated intracellular localization of PUS1p with
the use of publicly available prediction algorithms. Nei-
ther PSORTII or MITOPROT found evidence of a mi-
tochondrial targeting sequence. However, the determi-
nation of possible subcellular localization on the basis
of the global amino acid composition of proteins (Rein-
hardt and Hubbard 1998), with the use of the Neural
Networks Protein Subcellular Localization (NNPSL),
classified PUS1p as a likely mitochondrial enzyme.
NNPSL was used successfully to determine subcellular
localization of yeast mitochondrial pseudouridine syn-
thase (pus5p), which catalyzes formation of a single
pseudouridine in the yeast 21S mt rRNA (Ansmant et
al. 2000). Yeast pus5p also had no evidence of a mi-
tochondrial targeting sequence (Ansmant et al. 2000).
We evaluated PUS1 expression by RT-PCR, using
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Table 1
Summary of Sequence Changes in the Candidate Genes for MLASA in the 1.2-Mb Region of Chromosome 12q24.33
Gene
GenBank
Accession
Number Exons
Protein
Length
(aa)
Variation(s) from
GenBank Sequence
Heterozygous
in Carrier,
Homozygous
in Affected Amino Acid Change
Polymorphic in
Human EST
Database or
Known SNPa
SFRS8 NM004592 19 951 T1402C Nob LeurPro SNP rs1982528
MMP17 NM016155 10 606 None
ULK1 NM003565 26 1,050 C2539A Yes No No
PUS1 NM025215 6 399 C656T Yes ArgrTrp No (0/48)
EP400 NM015409 53 3,124 G9319A Yes Alar Thr ESTs (2/19)
FLJ33915 NM182613 9 430 A588G Yes AsprGly ESTs (3/11)
G973A Yes No No
C1199T Yes HisrTyr ESTs (4/8)
DDX51 NM175066 13 666 G896A Yes ArgrGly SNP rs7958174
G977A Yes AlarVal ESTs (11/21)
T1823C Yes No No
MCC3162 NM024078 15 516 None
hCG1820940c None 3 127 None
GALNT9 NM021808 7 237 None
NOTE.—Genes are arranged in order from centromere to telomere. The disease-causing mutation in the PUS1 gene is in bold italics.
a Number of ESTs containing variant sequence and total number of ESTs are shown in parentheses for sequence changes identified
in the EST database.
b SNP is homozygous in both.
c Celera database only.
RNA from lymphoblastoid cell lines from our patients
with MLASA and from controls, as well as RNA from
normal liver, brain, heart, bone marrow, and skeletal
muscle. A single PCR product of expected size in all
samples was obtained (data not shown). Quantitative
expression analysis, with the use of Assay-On-Demand
(Applied Biosystems) gene expression product, showed
elevated levels of expression in skeletal muscle and brain
(∼14 and ∼6 times more than in bone marrow, respec-
tively; see also fig. 3). Although our electronic BLAST
search analysis, as well as RT-PCR analysis, of the ESTs
of multiple normal human tissues indicated existence of
a single transcript, expression studies of the mouse pus1
gene showed that several differentially spliced shorter
isoforms, none catalytically active on tRNA substrates,
exist (Chen and Patton 2000). The function of these
isoforms is unknown, but they are speculated to be in-
volved in the dimerization of the active mouse pus1p.
The existence of similar isoforms in normal human tis-
sues has not been identified at this time.
Mutations in another pseudouridine synthase,
coded by the dyskerin gene (DKC1 [accession number
NM001363]), have been implicated in two human dis-
eases associated with bone marrow dysfunction, X-
linked dyskeratosis congenita (MIM 305000) (Heiss et
al. 1998; Luzzatto and Karadimitris 1998; Knight et
al. 1999b, 2001) and Hoyeraal-Hreidarsson (MIM
300240) syndrome (Knight et al. 1999a; Yaghmai et al.
2000). Reduced pseudouridylation with 10%–40% re-
duction in pseudouridines in the 28S and 18S mouse
rRNA have been shown in a mouse model for dysker-
atosis congenita (Ruggero et al. 2003).
Although no enzyme for mitochondrial pseudouri-
dylation in humans has been described, indirect evidence
suggests that pseudouridylation of human mitochondrial
tRNAs requires PUS1p. Yeast and mouse homologs of
PUS1p have been shown to catalyze the formation of
pseudouridines at specific positions in cytoplasmic
tRNAs (Hellmuth et al. 2000; Huang et al. 1998; Mo-
torin et al. 1998; Chen and Patton 1999, 2000; Foster
et al. 2000). Also, plant mitochondrial tRNA has been
shown to contain a pseudouridine at the corresponding
site to the cytoplasmic tRNA (Fey et al. 2002). We know
that at least one pseudouridine is known to be univer-
sally present in almost all mitochondrial tRNAs from
all three kingdoms (Sprinzl et al. 1998). Interestingly,
the T8356C mutation associated with the mitochondrial
syndromes MERRF (MIM 545000) and MELAS (MIM
540000) (Silvestri et al. 1992; Zeviani et al. 1993) is
adjacent to the universally present pseudouridine in mi-
tochondrial tRNA Lys. It has been shown that yeast
pseudouridine synthase 4 (pus4p) is responsible for the
catalysis of the uridine at this position in cytoplasmic
and mitochondrial tRNAs (Becker et al. 1997) and that
yeast pus1p is indispensable for cell viability in the pres-
ence of pus4p mutations (Grosshans et al. 2001).
In summary, the assertion that the homozygous
C656T mutation in the PUS1 gene is the pathogenic
mutation in two families with MLASA is supported by
the following points: (1) within the 1.2-Mb candidate
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Figure 2 Evolutionary conservation of the human 116R (arginine) residue in the eukaryotic and prokaryotic homologues of PUS1p.
Percent identity was calculated by ALIGN (Pearson et al. 1997). GenBank accession numbers of the sequences, in the order of appearance (top
to bottom): Homo sapiens NP079491, Mus musculus NM019700, Rattus norvegicus XM222267, Bos taurus CB440130, Danio rerio BC050502,
Drosophila melanogaster NM142642, Caenorhabditis elegans T26253, Saccharomyces cerevisiae Q12211, S. cerevisiae P53167, C. elegans
Q09524, S. cerevisiae P31115, Methanothermobacter thermautotrophicus O26928, Arabidopsis thaliana O22928, Escherichia coli P07649,
Clostridium perfringens Q8xlq0, Haemophilus influenzae p45291, Clostridium muridarum Q9PJT0.
Figure 3 Quantitative analysis of PUS1 expression in different
tissues. dCt indicates the difference between Ct (PUS1) and Ct
(GAPDH).
region delineated by genetic mapping, it is the only mu-
tation in the coding region of all appropriately expressed
genes that changes an amino acid and is not a previously
described polymorphism; (2) the mutation is present in
homozygous form in all patients, and in heterozygous
form in all obligate carriers (parents); (3) the mutation
was not found in 934 controls from different ethnic
backgrounds, including Jewish, and was not present in
any of the 48 available ESTs; (4) the mutation constitutes
a nonconservative change; (5) the mutation affects an
amino acid that has been conserved throughout evolu-
tion, including in prokaryotes; (6) the mutation appears
to be in the catalytic center of the protein; (7) the in-
tracellular localization of the protein is predicted to be
in the mitochondria on the basis of its amino acid com-
position; (8) a defect in pseudouridylation has been dem-
onstrated in a mouse model for dyskeratosis congenita,
another tissue-restricted syndrome that affects the bone
marrow; (9) indirect evidence suggests that pseudouri-
dylation of human mitochondrial tRNAs requires the
PUS1p; and (10) the gene is expressed in both skeletal
muscle and bone marrow. Though these points do not
completely rule out the possibility that an as-yet-unre-
cognized gene in the region harbors the actual disease
mutation, the weight of the evidence makes such a pos-
sibility highly unlikely. Further investigation of the role
of PUS1p and pseudouridylation in different tissues is
expected to lead to a better understanding of the patho-
physiology and tissue specificity of MLASA as well as
other oxidative phosphorylation disorders.
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